SCHEMBL3339342

SCHEMBL3339342

COc1cc(Cl)c(-c2nnc(-c3cn4cc(C(F)(F)F)cc(Cl)c4n3)o2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
NPC1 O15118 4/20 0.53
NFKB1 P19838 4/20 0.53
NFKB2 Q00653 4/20 0.53
RELA Q04206 4/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.47
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 2/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2478270 0.86 NPC1 (0.43) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3340971 0.85 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3343215 0.85 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3341149 0.84 SMN1; SMN2 (0.50) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3343184 0.82 NPC1 (0.40) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3340439 0.82 NPC1 (0.53) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3340331 0.81 NPC1 (0.42) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3340587 0.80 NPC1 (0.61) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL13331059 0.80 NPC1 (0.37) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL2499778 0.78 S1PR1 (0.38) RAB9ASMN1; SMN2NPC1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 RAB9A 2844/4885SMN1; SMN2 2046/4885NPC1 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.